StockMacro
Menu

Sean A. McCarthy

Insider (Form 4 reporting owner): CEO CIK 1654058Name as filed: McCarthy Sean A.Its filings on EDGARAll insiders

Measures activity, not value. Not investment advice.

Since 3 Mar 2017, sold $8.6M in 36 sales (2 under a 10b5-1 plan set in advance) of CytomX Therapeutics.

Companies

Role on the latest Form 4 for each; open-market trades counted
CompanyRoleTrades fromtoPurchasesSales
CytomX Therapeutics CTMXCEO3 Mar 201717 Mar 2026–36$8.6M

What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.

Median return minus the sector fund, in percentage points; "too few trades" under 5
Open-market tradesAfter 3 monthsAfter 6 monthsAfter 12 months
After sales-40.0 pts29 trades, 14% above the sector-77.3 pts29 trades, 14% above the sector-76.5 pts28 trades, 18% above the sector

For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.

By year

Counted open-market trades, by trade date
YearPurchasesBoughtSalesSoldNet
2026––1$764K-$764K
2025––3$634K-$634K
2024––2$59K-$59K
2023––3$51K-$51K
2022––1$21K-$21K
2021––2$1.5M-$1.5M
2020––1$540K-$540K
2018––9$2.4M-$2.4M
2017––14$2.7M-$2.7M

Every trade

39, newest first; open-market purchases and sales only
Trade dateCompanySideSharesPriceValuePlanned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. Filing
17 Mar 2026CytomX Therapeutics CTMXSell118,969$6.42$764K10b5-1 planForm 4filed 19 Mar 2026
6 Nov 2025CytomX Therapeutics CTMXSellamended filing (4/A), not counted again; after exercising options101,793$4.54$462K10b5-1 planForm 4/Afiled 16 Oct 2026
6 Nov 2025CytomX Therapeutics CTMXSell101,793$4.54$462K10b5-1 planForm 4filed 10 Nov 2025
16 Jun 2025CytomX Therapeutics CTMXSellafter exercising options55,511$2.69$149KNoForm 4filed 17 Jun 2025
18 Mar 2025CytomX Therapeutics CTMXSell37,656$0.60$23KNoForm 4filed 20 Mar 2025
20 Aug 2024CytomX Therapeutics CTMXSellafter exercising options13,898$1.23$17KNoForm 4filed 22 Aug 2024
19 Mar 2024CytomX Therapeutics CTMXSell20,223$2.09$42KNoForm 4filed 21 Mar 2024
20 Dec 2023CytomX Therapeutics CTMXSell13,551$1.38$19KNoForm 4filed 22 Dec 2023
22 Sep 2023CytomX Therapeutics CTMXSell14,601$1.30$19KNoForm 4filed 22 Sep 2023
16 Mar 2023CytomX Therapeutics CTMXSell7,121$1.88$13KNoForm 4filed 20 Mar 2023
20 Jul 2022CytomX Therapeutics CTMXSell14,911$1.42$21KNot statedForm 4filed 21 Jul 2022
16 Jun 2021CytomX Therapeutics CTMXSell100,000$7.04$704KNot statedForm 4filed 21 Jun 2021
31 Mar 2021CytomX Therapeutics CTMXSellafter exercising options100,000$7.49$749KNot statedForm 4filed 2 Apr 2021
12 May 2020CytomX Therapeutics CTMXSellafter exercising options36,000$15.00$540KNot statedForm 4filed 14 May 2020
1 Nov 2018CytomX Therapeutics CTMXSellafter exercising options6,526$15.00$98KNot statedForm 4filed 5 Nov 2018
4 Sep 2018CytomX Therapeutics CTMXSellafter exercising options13,052$21.86$285KNot statedForm 4filed 6 Sep 2018
5 Jul 2018CytomX Therapeutics CTMXSellafter exercising options4,497$25.06$113KNot statedForm 4filed 9 Jul 2018
3 Jul 2018CytomX Therapeutics CTMXSellafter exercising options2,028$25.09$51KNot statedForm 4filed 6 Jul 2018
2 Jul 2018CytomX Therapeutics CTMXSellafter exercising options13,052$23.42$306KNot statedForm 4filed 3 Jul 2018
1 May 2018CytomX Therapeutics CTMXSellafter exercising options19,578$26.55$520KNot statedForm 4filed 2 May 2018
1 Mar 2018CytomX Therapeutics CTMXSellafter exercising options19,578$29.43$576KNot statedForm 4filed 5 Mar 2018
5 Jan 2018CytomX Therapeutics CTMXSellafter exercising options6,526$25.01$163KNot statedForm 4filed 9 Jan 2018
2 Jan 2018CytomX Therapeutics CTMXSellafter exercising options13,052$21.04$275KNot statedForm 4filed 4 Jan 2018
1 Dec 2017CytomX Therapeutics CTMXSellafter exercising options14,340$20.60$295KNot statedForm 4filed 5 Dec 2017
1 Nov 2017CytomX Therapeutics CTMXSellafter exercising options14,342$19.86$285KNot statedForm 4filed 3 Nov 2017
4 Oct 2017CytomX Therapeutics CTMXSellafter exercising options19,120$24.13$461KNot statedForm 4filed 6 Oct 2017
2 Oct 2017CytomX Therapeutics CTMXSellafter exercising options9,562$18.57$178KNot statedForm 4filed 4 Oct 2017
1 Sep 2017CytomX Therapeutics CTMXSellamended filing (4/A), not counted again; after exercising options9,930$17.33$172KNot statedForm 4/Afiled 22 Sep 2017
1 Sep 2017CytomX Therapeutics CTMXSellafter exercising options9,930$17.32$172KNot statedForm 4filed 5 Sep 2017
31 Aug 2017CytomX Therapeutics CTMXSellamended filing (4/A), not counted again; after exercising options18,756$17.50$328KNot statedForm 4/Afiled 22 Sep 2017
31 Aug 2017CytomX Therapeutics CTMXSellafter exercising options18,756$17.50$328KNot statedForm 4filed 1 Sep 2017
9 Aug 2017CytomX Therapeutics CTMXSellafter exercising options4,781$15.00$72KNot statedForm 4filed 11 Aug 2017
3 Jul 2017CytomX Therapeutics CTMXSellafter exercising options4,781$15.52$74KNot statedForm 4filed 6 Jul 2017
26 Jun 2017CytomX Therapeutics CTMXSellafter exercising options4,481$15.00$67KNot statedForm 4filed 27 Jun 2017
5 Jun 2017CytomX Therapeutics CTMXSellafter exercising options300$15.00$4KNot statedForm 4filed 6 Jun 2017
1 May 2017CytomX Therapeutics CTMXSellafter exercising options4,781$15.70$75KNot statedForm 4filed 2 May 2017
3 Apr 2017CytomX Therapeutics CTMXSellafter exercising options9,562$17.22$165KNot statedForm 4filed 5 Apr 2017
20 Mar 2017CytomX Therapeutics CTMXSellafter exercising options14,343$19.60$281KNot statedForm 4filed 21 Mar 2017
3 Mar 2017CytomX Therapeutics CTMXSellafter exercising options14,343$15.00$215KNot statedForm 4filed 3 Mar 2017

From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.